We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 123

Pfizer v Ranbaxy; 55.2 proceeding; October 5, 2007 - atorvastatin

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • October 25 2007

The trial judge granted prohibition in respect of one patent claiming a novel crystalline form of atorvastatin (the "crystalline form patent") and denied prohibition in respect of another patent claiming a novel process for making atorvastatin (the "process patent"

AstraZeneca v. Novopharm, appeal of decision to strike Statement of Claim

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 21 2010

This was an appeal to the Federal Court of Appeal (FCA) of the decision of Justice Hughes to strike AstraZeneca's Statement of Claim

Pfizer v Apotex; decision on the merits of a 55.2 proceeding; January 4, 2008; drug: atorvastatin

  • Gowling Lafleur Henderson LLP
  • -
  • USA
  • -
  • February 7 2008

The Trial Division found the patent at issue to be invalid as it did not meet the test for a valid selection, and it claimed subject matter that was already the subject of a previous patent

Merck v. Pharmascience, PMNOC Regulations decision

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 21 2010

The Court, in a lengthy decision, dismissed an application for prohibition in respect of the drug finasteride, wherein allegations of invalidity had been raised, including grounds of double-patenting, novelty and obviousness

Pfizer v. Novopharm, interlocutory motion in PMNOC Regulations case

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 21 2010

Novopharm served a NOA on Pfizer which it had designated confidential

Second phase of Alberta's pharmaceutical strategy aims to reduce drug costs, improve access to new drugs and expand the role of pharmacists

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 2 2009

On October 20, 2009, the Alberta Government released the second phase of the Alberta Pharmaceutical Strategy which indicates that the Government will reduce generic drug prices - the Government states it will reduce the price of new generic drugs from 75 percent of the brand name drug to 45 and announces that its discussions with pharmacists and pharmacies regarding the price reduction will begin this month

Celgene v. Canada

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 24 2009

Celgene is the current owner of several patents relating to thalidomide

Sanofi-Aventis v. Laboratoire Riva; interlocutory motion on 55.2 proceeding; December 14, 2007 - Ramipril

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • January 17 2008

After cross-examinations had taken place, and approximately one week before the application record of Sanofi-Aventis was due, Riva brought a motion for leave to file further evidence

AstraZeneca v Novopharm, motion to adduce video-recordings of cross-examinations of expert witnesses in a PMNOC Regulations case

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 21 2010

AstraZeneca brought a motion seeking an order that video-recordings of cross-examinations of expert witnesses in the proceedings be filed as part of the Application Record and available at the hearing

Lundbeck v. Cobalt, Genpharm and Apotex

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 7 2009

The Court granted prohibition in respect of each of the proceedings against each defendant